Effect of adsorbents on the absorption of lansoprazole with surfactant

被引:53
作者
Ito, Y [1 ]
Arai, H [1 ]
Uchino, K [1 ]
Iwasaki, K [1 ]
Shibata, N [1 ]
Takada, K [1 ]
机构
[1] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto, Japan
关键词
lansoprazole; absorption; bioavailability; adosorbent; surfactant; oral administration;
D O I
10.1016/j.ijpharm.2004.10.010
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Lansoprazole (LPZ) is a representative drug that shows a high inter-subject variation of bioavailability (BA). Solid preparation composed of surfactant, adsorbent and LPZ were prepared to improve the dissolution and absorption of LPZ, and the BA of LPZ was measured in rats and dogs. As surfactant, Tween 80, polyoxy 60 hydrogenated caster oil derivative (HCO-60) and PEG-8 caprylic/capric glycerides (Labrasol) were used. As adsorbant, porous silicon dioxide (Sylysia 550, 320), magnesium aluminometa silicate (Neusilin S-2, NS2N, US2,) and porous calcium silicate (Florite RE) were used. After small intestinal administration of LPZ, 5.0 mg/kg, solution with HCO-60 showed the highest plasma LPZ concentration versus time curve of which C-max and AUC was 0.46 +/- 0.01 mug/mL and 0.73 +/- 0.03 mug h/mL. By comparing to that after i.v. injection of LPZ solution, 2.0 mg/kg, the BA of LPZ from HCO-60 solution was 39.0%, which was about seven times higher than that of LPZ powder. To solidify the LPZ solution with HCO-60, adsorbents were used and the obtained solid preparations were used for in vitro release experiment. Sylysia 320, Neusilin S-2 and Neusilin NS2 showed the T50% of about 1 h. To evaluate the BA of these solid preparations, absorption study was performed in rats. Sylysia 550 system showed the higher AUC than other systems, showing the BA of 28.1%. Sylysia 550 system was filled in an enteric capsule and was orally administered to dogs and BA was compared with enteric tablet. The AUC of Sylysia 550 system was 2.16 +/- 0.26 mug h/mL and was greater than enteric tablet and the BA of 71.7% was obtained. Solid system composed of LPZ, surfactant and adsorbent has suggested the possibility as a good tool to improve the BA of LPZ. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:69 / 77
页数:9
相关论文
共 20 条
[1]
A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]
PHARMACOKINETICS OF VARIOUS SINGLE INTRAVENOUS AND ORAL DOSES OF OMEPRAZOLE [J].
ANDERSSON, T ;
CEDERBERG, C ;
REGARDH, CG ;
SKANBERG, I .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (02) :195-197
[3]
HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF LANSOPRAZOLE AND ITS METABOLITES IN HUMAN SERUM AND URINE [J].
AOKI, I ;
OKUMURA, M ;
YASHIKI, T .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1991, 571 (1-2) :283-290
[4]
Formulation and in vivo evaluation of omeprazole buccal adhesive tablet [J].
Choi, HG ;
Jung, JH ;
Yong, CS ;
Rhee, CD ;
Lee, MK ;
Han, JH ;
Park, KM ;
Kim, CK .
JOURNAL OF CONTROLLED RELEASE, 2000, 68 (03) :405-412
[5]
VARIATION IN GASTROINTESTINAL TRANSIT OF PHARMACEUTICAL DOSAGE FORMS IN HEALTHY-SUBJECTS [J].
COUPE, AJ ;
DAVIS, SS ;
WILDING, IR .
PHARMACEUTICAL RESEARCH, 1991, 8 (03) :360-364
[6]
Pharmacokinetics and absolute bioavailability of lansoprazole [J].
Gerloff, J ;
Mignot, A ;
Barth, H ;
Heintze, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (04) :293-297
[7]
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease [J].
Hatlebakk, JG ;
Berstad, A .
CLINICAL PHARMACOKINETICS, 1996, 31 (05) :386-406
[8]
Iwasaki Koji, 2004, Drug Metab Pharmacokinet, V19, P227, DOI 10.2133/dmpk.19.227
[9]
Evaluation of an intestinal pressure-controlled colon delivery capsules prepared by a dipping method [J].
Jeong, YI ;
Ohno, T ;
Hu, ZP ;
Yoshikawa, Y ;
Shibata, N ;
Nagata, S ;
Takada, K .
JOURNAL OF CONTROLLED RELEASE, 2001, 71 (02) :175-182
[10]
IMPLANTABLE SLOW-RELEASE CYCLOSPORINE A(CYA) DELIVERY SYSTEM TO THORACIC LYMPH DUCT [J].
KATAYAMA, N ;
TANAKA, R ;
OHNO, Y ;
UEDA, C ;
HOUJOU, T ;
TAKADA, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 115 (01) :87-93